Astria Therapeutics Inc. (ATXS)
NASDAQ: ATXS
· Real-Time Price · USD
6.96
0.20 (2.96%)
At close: Aug 15, 2025, 2:35 PM
2.96% (1D)
| Bid | 6.93 |
| Market Cap | 392.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -108.04M |
| EPS (ttm) | -2.02 |
| PE Ratio (ttm) | -3.45 |
| Forward PE | -2.69 |
| Analyst | Buy |
| Ask | 6.96 |
| Volume | 249,215 |
| Avg. Volume (20D) | 360,808 |
| Open | 6.82 |
| Previous Close | 6.76 |
| Day's Range | 6.78 - 7.14 |
| 52-Week Range | 3.56 - 12.92 |
| Beta | 0.48 |
About ATXS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ATXS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ATXS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Astria Therapeutics Inc. is scheduled to release its earnings on
Nov 12, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · businesswire.com
Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare ConferenceBOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that ...
2 months ago · businesswire.com
Astria Therapeutics to Present at Upcoming Eastern Allergy ConferenceBOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that ...